The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ripretinib versus sunitinib in imatinib-resistant gastro-intestinal stromal tumor with KIT Exon 11 mutations: A systematic review and meta-analysis.
 
Sandeep Guntuku
No Relationships to Disclose
 
Sripada Preetham Kasire
No Relationships to Disclose
 
Krishna Doshi
No Relationships to Disclose
 
Nandhini Iyer
No Relationships to Disclose
 
Laxman Yashwant Byreddi
No Relationships to Disclose
 
Sugam Gouli
No Relationships to Disclose
 
Ravi Paluri
Honoraria - Exelixis; Ipsen; Seagen
Consulting or Advisory Role - Exelixis; Ipsen
Speakers' Bureau - Exelixis; Ipsen
Research Funding - Geistlich Pharma; Minneamrita Therapeutics; Seagen
 
Ashish Manne
Honoraria - Onclive
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Cardinal Health
 
Anup Kasi
Consulting or Advisory Role - Cardinal Health; Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Boundless Bio (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novita Pharmaceuticals (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)